Literature DB >> 34202354

Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations for Understanding the Underlying Biology and Molecular Pathogenesis.

Mohammad Mahmud Hossain1, Kentaro Nakayama1, Kamrunnahar Shanta1, Sultana Razia1, Masako Ishikawa1, Tomoka Ishibashi1, Hitomi Yamashita1, Seiya Sato1, Kouji Iida1, Kosuke Kanno1, Noriyoshi Ishikawa2, Tohru Kiyono3, Satoru Kyo1.   

Abstract

Endometriosis-harboring cancer-associated somatic mutations of PIK3CA and KRAS provides new opportunities for studying the multistep processes responsible for the functional and molecular changes in this disease. We aimed to establish a novel in vitro endometriosis model to clarify the functional behavior and molecular pathogenesis of this disorder. Immortalized HMOsisEC10 human ovarian endometriotic epithelial cell line was used in which KRAS and PIK3CA mutations were introduced. Migration, invasion, proliferation, and microarray analyses were performed using KRAS and PIK3CA mutant cell lines. In vitro assays showed that migration, invasion, and proliferation were significantly increased in KRAS and PIK3CA mutant cell lines, indicating that these mutations played causative roles in the aggressive behavior of endometriosis. Microarray analysis identified a cluster of gene signatures; among them, two significantly upregulated cancer-related genes, lysyl oxidase (LOX) and pentraxin3 (PTX3), were associated with cell proliferation, invasion, and migration capabilities. Furthermore, siRNA knockdown of the two genes markedly reduced the metastatic ability of the cells. These results suggest that endometriosis with KRAS or PIK3CA mutations can significantly enhance cell migration, invasion, and proliferation by upregulating LOX and PTX3. We propose that LOX and PTX3 silencing using small molecules could be an alternative therapeutic regimen for severe endometriosis.

Entities:  

Keywords:  KRAS; LOX; PIK3CA; PTX3; cell proliferation; epithelial cell line; invasion; microarray analysis; migration; ovarian endometriosis

Year:  2021        PMID: 34202354     DOI: 10.3390/cancers13133174

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Authors:  Kamrunnahar Shanta; Kentaro Nakayama; Mohammad Mahmud Hossain; Sultana Razia; Tomoka Ishibashi; Masako Ishikawa; Hitomi Yamashita; Kosuke Kanno; Seiya Sato; Satoru Nakayama; Yoshiro Otsuki; Satoru Kyo
Journal:  Curr Oncol       Date:  2022-06-01       Impact factor: 3.109

2.  Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.

Authors:  Takafumi Watanabe; Hideaki Nanamiya; Yuta Endo; Manabu Kojima; Shinji Nomura; Shigenori Furukawa; Shu Soeda; Hirosumi Tamura; Masae Ryufuku; Daisuke Tanaka; Takao Isogai; Jun-Ichi Imai; Shinya Watanabe; Keiya Fujimori
Journal:  J Ovarian Res       Date:  2021-10-06       Impact factor: 4.234

3.  Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells.

Authors:  Puja Dey; Kentaro Nakayama; Sultana Razia; Masako Ishikawa; Tomoka Ishibashi; Hitomi Yamashita; Kosuke Kanno; Seiya Sato; Tohru Kiyono; Satoru Kyo
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.